GIP AND GLP-1 CO-AGONIST COMPOUNDS

The present invention relates to dual incretin peptide mimetic compounds that agonize receptors for both human glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), and may be useful for treating type 2 diabetes mellitus (T2D).

GIP and GLP-1 co-agonist compounds

ORGANIC CHEMISTRY

Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof-by chemical synthesis

PEPTIDES 

MEDICAL OR VETERINARY SCIENCE; HYGIENE

Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof-from animals; from humans-Hormones 

Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00-Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES 

Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof-from animals; from humans-Hormones -Glucagons

Medicinal preparations containing peptides -Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof 

Medicinal preparations containing peptides 

Drugs for disorders of the metabolism -for glucose homeostasis -for hyperglycaemia, e.g. antidiabetics

Prosecution History analysis

Examiner Search analysis

Invalidity Framework analysis

General

Analytics

Cases

Patent Assignments

Citations